• Explore /
  • Poster
  • / A novel method that leverages existing data to conduct comparative analyses of competing assets: Sugemalimab and agents targeting the PD-L1/PD-1 axis as an example.

A novel method that leverages existing data to conduct comparative analyses of competing assets: Sugemalimab and agents targeting the PD-L1/PD-1 axis as an example.

Abstract Poster

Authors

null

Antonio Tito Fojo

Columbia University Medical Center, New York, NY

Antonio Tito Fojo , Mengxi Zhou , Meredith LaRose , Susan Elaine Bates , Lawrence Howard Schwartz

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

PD1/PD-L1 Inhibitor Combinations

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 2609)

DOI

10.1200/JCO.2023.41.16_suppl.2609

Abstract #

2609

Poster Bd #

451

Abstract Disclosures

Similar Posters

First Author: Nashat Gabrail

Poster

2024 ASCO Annual Meeting

<span>PD-L1 expression in pulmonary sarcomatoid carcinoma and response to immunotherapy.</span>

PD-L1 expression in pulmonary sarcomatoid carcinoma and response to immunotherapy.

First Author: Lingzhi Hong

First Author: Diane Damotte

First Author: Kohei Shitara